GT Biopharma (GTBP)

#NEWS | GT Biopharma Inc. $GTBP Begins Manufacturing of “Non-Opioid” Pain-Brake Drug bit.ly/GTBPnews

$GTBP to commence first-in-human Phase 1 study with its first-in-class TriKE, for the treatment of #AML, #MDS and mastocytosis bit.ly/2UnhaJw

$GTBP Positive preclinical findings highlight the clinical potential of the CLEC12A TriKE individually or in combination with the CD33 TriKE for the treatment of #MDS and #AML bit.ly/2UnhaJw

$GTBP proprietary TriKE product candidates have the potential to serve as a relatively safe, cost-effective, and easy-to-use therapy for refractory/relapsed #AML, high-risk #MDS and advanced systemic #mastocytosis bit.ly/2UnhaJw

$GTBP Presents Positive Preclinical Data of Tri-specific NK Cell Engager (TriKE) at the 60th @ASH_hematology Annual Meeting & Exposition bit.ly/2UnhaJw

$GTBP Announces Presentation of Two Abstracts at the 60th American Society of Hematology Annual Meeting & Exposition @ASH_hematology bit.ly/2DR6SvS

$GTBP Business Update - Continued progress of Phase 2a study of GTB-1550 with topline results expected in Q1 2019 bit.ly/2OLu5Ra

$GTBP Business Update - FDA clearance of IND to advance first-in-class TriKE, GTB-3550, into first-in-human Phase 1 study for the treatment of AML, MDS and mastocytosis marks significant regulatory milestone bit.ly/2OLu5Ra

$GTBP Reports Third Quarter 2018 Financial Results and Provides Business Update bit.ly/2OLu5Ra

“The clinical trials team at the #UniversityofMinnesota is excited to commence the Phase 1 trial testing this novel immunotherapeutic agent, GTB-3550,” said Dr. Cooley. #AML $GTBP bit.ly/2JuZ8zT

“GTB-3550 is a protein immune engager that binds to natural killer cells and targets them specifically to leukemia cells,” said renowned NK cell expert, Jeffrey Miller, MD, Deputy Director, Masonic Cancer Center, #University of Minnesota. $GTBP bit.ly/2JuZ8zT

$GTBP Receives FDA Clearance to Commence First-in-Human Phase 1 Study of its First-in-Class Tri-Specific Killer Engager (TriKE), GTB-3550, for the Treatment of #AcuteMyelogenousLeukemia, Myelodysplatic Syndrome and Mastocytosis. #AML bit.ly/2JuZ8zT

GT Biopharma Announces Completion of First Four Patients in FDA Phase 2 Trial of Cancer Drug OXS-1550 yhoo.it/2y7EX7D

$GTBP Conference Call from 10/02/2017 fccdl.in/h25zpQtLS

Check out the most recent Press Releases from $GTBP gtbiopharma.com/news-media/pre… @btstocks @marijuanastocks #cancerresearch #cancerfighter

$GTBP is Targeting multiple myeloma, triple-negative #breastcancer, non-Hodgkin's lymphoma and more with highly potent bio-pharmaceutical drugs designed for targeted therapy. @marijuanastocks @btstocks @technical420 @SusanGKomen #breastcancerawareness